Suscribirse

W2: Practical considerations when using oral fluid as toxicological matrix - 28/06/14

Doi : 10.1016/S2352-0078(14)70002-2 
S.M.R. Wille
 National institute of criminalistics and criminology, Laboratory of toxicology, Brussels, Belgium 

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 2
Iconografías 0
Vídeos 0
Otros 0

Resumen

Introduction

Over the last decades, the possibilities for monitoring the presence of drugs of abuse in oral fluid (OF) has increased enormously. Especially in the domain of testing drivers under influence of drugs (DUID), OF has gained popularity due to its non-invasive collected, directly on-site without hampering privacy. Several on-site immunosorbent tests (OIT) were developed over the years. For confirmatory analysis, the use of OF has been hampered by the influence of the salivary composition on the final drug concentrations. The OF collection protocol, the degree of stimulation of salivary flow, the physicochemical properties of drugs of abuse, and the type of drug administration are some of the parameters that influence the OF drug concentrations. Moreover, the final analytical result will be influenced by the OF collection. As a result, toxicological analysis of OF samples and the final interpretation is not always straightforward.

Methods

Laboratory and roadside studies, as well as double-blind placebo-controlled studies are used to evaluate the problems encountered using OF as confirmation matrix. The focus is put on Δ9-tetrahydrocannabinol (THC) analysis. The placebo-controlled study involves 10 test subjects smoking two subsequent doses of THC; 300μg/kg and 150μg/kg with a pause of 75 minutes using a Volcano vaporizer. Using the above mentioned studies, OIT (Drug-Test®, Drager and Drugwipe®, Securetec) and several OF collection devices (StatSure®, Diagnostic Systems Inc; Quantisal®, Immunalysis and Certus®, Concateno) will be evaluated via UPLC-MS/MS analysis.

Results

Sensitivity of OIT seem to increase. The DrugTest 5000 and Drugwipe demonstrated respectively a sensitivity of 93% and 72% for Δ9-tetrahydrocannabinol during roadside studies. The Drugwipe is very sensitive just after smoking, but it rapidly decreases within 1.5 hours.

The type of OF collection has to be specified when using OF as confirmation matrix, as THC recovery ranged from 50 to 70% and is dependent on the storage conditions. While matrix effects due to the collector buffers are observed, stability is often guaranteed via the stabilizing buffers. In a roadside study, we observed that after 5 minutes collection time, about 0.11–1.15mL of OF was collected. Therefore, the final drug concentrations in neat OF have to be calculated via the following formula: C = [CUPLC/MS · (V1 + (W1–W2))] / [V2 x (W1–W2)] with C being the drug concentration in neat OF, CUPLC/MS the concentration obtained via the calibration curve, V1 the buffer volume, V2 the theoretical total collected volume and W1 and W2 respectively the weight of the collection device after and before OF collection. Neat OF THC concentrations in the placebo controlled study ranged from 12,361ng/g 5 minutes after smoking down to 34ng/g 80 minutes after 2 smoking sessions. Under placebo conditions, a median of 8ng/g THC in OF was observed. The impact of all these observations on DUID legislations will be discussed.

Conclusion

OF has its limitations as a toxicological matrix. However, in situations where ‘recent’ drug use in combination with analytical cut-offs for interpretations are used, OF combines an easy collection of samples with a quick analysis of large batches.

El texto completo de este artículo está disponible en PDF.

Esquema

Plan inalienable

© 2014  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 26 - N° 2S

P. S1-S2 - juin 2014 Regresar al número
Artículo precedente Artículo precedente
  • W1: Overview of oral fluid as toxicological matrix
  • A. Verstraete
| Artículo siguiente Artículo siguiente
  • W3: The French experience of establishing an oral fluid roadside drug test
  • O. Roussel, M. Perrin-Rosset, C. Fuché, M. Carlin

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.